



## URGENT: DRUG RECALL

Important Note: This recall letter is being re-issued following reclassification from Class III to Class II by the U.S. Food and Drug Administration. Please notify your customers accordingly.

Dear Customer:

June 2, 2026

This is to inform you of a product recall involving Metoprolol Succinate Extended-Release (ER) Tablets USP, 25 mg. Please reference lot-specific information included below.

	Product Name	Lot Number	Strength	Expiration Date	Pack Size	NDC	Initial Distribution Date	Quantity Distributed (in bottles)
1	Metoprolol Succinate Extended-Release Tablets USP	25140859	25 mg	January 31, 2027	100 tablets/bottle	67877-590-01	6/17/2025	17,304 bottles

See enclosed product labels for ease in identifying the product at the RETAIL level.

An out-of-specification (OOS) result was observed during dissolution test analysis during long term stability testing (LT conditions:  $25 \pm 2$  °C /  $60 \pm 5$  % RH) of Metoprolol Succinate ER Tablets USP, 25 mg, for batch number 25140859.

Metoprolol Succinate is indicated for hypertension in patients six years of age and older as well as for angina pectoris and heart failure in adult patients. The dissolution data show a limited acceleration of drug release confined to the 8-hour time point, while all other intervals and 12-month stability results remain within specification, confirming the integrity of the extended-release profile. As this represents a marginal terminal-phase release acceleration without evidence of dose dumping or uncontrolled delivery, the deviation is not expected to be clinically significant and constitutes a minor health hazard at most.

Our firm began shipping this product on June 17, 2025. Immediately examine your inventory and quarantine product subject to recall for the lot number specified in the table above.

Please perform the following activities:

- Immediately examine your inventory and quarantine product subject to recall for the lot numbers specified in the table above. Please follow the directions in the attached recall stock response to return the affected product.
- Promptly complete the attached recall stock response form even if you have no product to return.
- The completed Recall Response Form can be submitted by any of the following methods:

Fax: 817-868-5362 or E-mail: [rxrecalls@inmar.com](mailto:rxrecalls@inmar.com)

This recall is being carried out to the RETAIL level. Your assistance is appreciated and necessary to prevent consumer harm.

Your assistance is appreciated and necessary in this voluntary recall. If you have any questions related to customer service, please contact product inquiries—available 24 hours a day, 7 days a week—at 877-272-7901. If you have any questions about the return of the product, please contact Inmar toll free at 855-735-7360—available 9:00 AM to 5:00 PM ET Monday through Friday (excluding holidays).

This recall is being conducted with the knowledge of the Food and Drug Administration.

Sincerely,

**Hindy Schiff**  
Digitally signed by Hindy Schiff  
Date: 2026.06.01 16:50:59 -04'00'

Hindy Schiff

Vice President, Regulatory Affairs and Compliance



\*Each film-coated tablet contains 23.75 mg metoprolol succinate, USP equivalent to 25 mg of metoprolol tartrate, USP.

**USUAL DOSAGE:** See package insert.

**WARNING:** As with all medications, keep out of the reach of children.

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). (See USP Controlled Room Temperature.)

Manufactured by: Alkem Laboratories Ltd., INDIA.  
Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054

NDC 67877-590-01

**Metoprolol Succinate Extended-Release Tablets, USP**

**25 mg\***

ASCEND LABORATORIES, LLC

Rx Only 100 Tablets

**CAUTION**  
Verify Product Dispensed

2367877590011

Code No: 00DRUGS00230 PL14079-01

Unvarnished area 45 x 20 mm (LxH)  
Rest label should be with UV Varnish

Alkem Laboratories Limited			
Product: Metoprolol Succinate Extended-Release Tablets, USP 25 mg	Market: Ascend, US	Size: (L x H) 115 x 25 mm	
Itemcode: PL14079-01	Version No: 01	Superseed No: PL14079	Mfg Location: Amaliya
PANTONE 185 C    PANTONE Yellow C Pantone No: Black    PANTONE 2725 C    PANTONE 265 C    PANTONE 171 C    PANTONE Blue 072 C    Pack Size: 100's			
Component: Label	Style: Roll Form	Substrate: 80 gsm chromo paper/20 gsm Hot-melt adhesive/65gsm release paper	
Change Part No: NA	Pharmacode: 2972	Barcode: N367877590011	
Reason for Issue: Address, Lic No. Label Size change along with Text and Barcode orientation change.		Change Control No: Q/CC/P/2021/0586 (PR ID - 62468)	
Date of Initiation: 08-11-2021		Final Approval of artwork:	
Modification Date:	*Space between two labels should NMT 10 mm		

**RECALL STOCK RESPONSE FORM**

**Recall: Metoprolol Succinate Extended-Release Tablets USP, 25 mg**

**Lot Number: 25140859**

Customer Name: \_\_\_\_\_ DEA #: \_\_\_\_\_

**\*Please note that DEA # is required. If it is not provided, the processing of your form will be delayed. \***

Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip Code: \_\_\_\_\_

Contact Name (please print): \_\_\_\_\_ Telephone #: \_\_\_\_\_

Contact Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Wholesaler Information if not directly purchased from Ascend:

Wholesaler Name: \_\_\_\_\_ Wholesaler DEA#: \_\_\_\_\_

Wholesaler City: \_\_\_\_\_ Wholesaler State: \_\_\_\_\_ Wholesaler Zip: \_\_\_\_\_

**Please check and fill out each section accordingly.**

- I have read and understand the recall instructions provided in the Recall Letter.
- I have checked my stock for the quarantined inventory indicated in the table below.

	Product Name	Lot Number	Strength	Expiration Date	Pack Size	NDC	Quantity on Hand (in bottles)
1	Metoprolol Succinate Extended-Release Tablets USP	25140859	25 mg	January 31, 2027	100 tablets/bottle	67877-590-01	
Total Product							

- Indicate disposition of recall product:
  - Returned/Held for Return (Yes / No)
    - Quantity: \_\_\_\_\_
    - Date: \_\_\_\_\_
    - Method: \_\_\_\_\_

**OR**

- No recall product on hand (Yes / No)
- I have identified and notified my customers that this product was shipped/received or may have been shipped by:

- Date: \_\_\_\_\_
- Method of Notification: \_\_\_\_\_

Were there any adverse events associated with the recalled product?

- Yes
- No

If yes, please explain: \_\_\_\_\_

If you have any questions regarding this form or product return, please contact Inmar at 1-855-735-7360.  
Office Hours: 9:00 AM to 5:00 PM EST Monday through Friday (excluding holidays).

Please return this form by fax to 1-817-868-5362 or E-mail [rxrecalls@inmar.com](mailto:rxrecalls@inmar.com).

After receipt of this response form, a return kit will be provided for affected product return to:

Inmar Rx Solutions  
3845 Grand Lakes Way  
Grand Prairie, TX, 75050

**Inmar Recall Event ID: RCL087-2026**